Press Releases

BioNTech SE  and Medigene AG , a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, today announced that they have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer. The initial term of the collaboration is three years. Medigene will contribute its proprietary TCR discovery platform for the development of TCRs against multiple solid tumor targets nominated by BioNTech. M

OKYO Pharma Limited , a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, is pleased to announce that it has today issued 403,719,360 new ordinary shares of no par value ("Ordinary Shares"), credited as fully paid on conversion of all outstanding convertible loan notes (“Conversion”) and the cashless exercise of all outstanding warrants, including those resulting from the Conversion.

A new collection of caps, vials, inserts, kits, well plates and mats improves analytical performance and sample security for chromatography and mass spectrometry users in routine and research laboratories, across a diverse range of sectors such as pharma, biopharma, clinical, food, environmental and academia. The Thermo Scientific SureSTART portfolio is compatible with all add-on and chromatography autosamplers, allowing analysts to use the new portfolio regardless of the instrument

BeiGene, a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today announced that BeiGene’s BTK inhibitor BRUKINSA (zanubrutinib) received approval from Swissmedic for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior line of therapy, or for treatment-naïve patients who are not suited for standard chemo-immunotherapy. BRUKINSA had previously been granted orp

Quoin Pharmaceuticals Ltd.  a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has entered into an exclusive Distribution Agreement with Neopharm Medical Supplies, an exclusive distributor for leading medical and pharma manufacturers in Israel, for QRX003, the Company’s investigational treatment for Netherton Syndrome, a rare and devastating genetic disease for which there is current

Medunik USA is pleased to announce that Siklos® (hydroxyurea), previously indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises4, has now been approved for use in adults for the same indication. Siklos® has a Boxed Warning regarding low blood cell counts and cancer; please read Important Safety Information below

POXEL SA , a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PXL065 for the treatment of patients with adrenomyeloneuropathy (AMN), the most common form of X-linked adrenoleukodystrophy (ALD). PXL065 is a novel, propr

 Kairos Pharma, Ltd.  a privately held clinical stage biotechnology company focused on drug resistance and immunotherapy for cancer, today announced that it has received FDA approval to proceed with a Phase 2 clinical trial of ENV105 with apalutamide for the treatment of metastatic castration-resistant prostate cancer. The phase II trial is sponsored by Enviro Therapeutics, a wholly-owned subsidiary of Kairos Pharma.  Kairos CEO John Yu, M.D. commented, "This IND

Virpax® Pharmaceuticals, Inc.  a company specializing in developing non-addictive product candidates for pain management, as well as PTSD, CNS disorders and anti-viral indications, has been featured in several news outlets discussing potential solutions for two pressing issues: the opioid epidemic and the COVID pandemic. An article published by BioBuzz titled “Pain Management Company Virpax Sees Promise in Potential COVID-19 Antiviral OTC” focuses on the drug ca

Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2022)covers the current state of the pharmaceutical manufacturing and packaging industry. The Congress gathers pharmaceutical companies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies. It will take place on June, 20-21, 2022 in Berlin, Germany. One of the major challenges for pharmaceutical executives is to manage the leveraging manufacturing and packaging proce